Abstract
In this issue of Blood, the first prospective trial of unrelated donor bone marrow transplantation (BMT) in children with sickle cell disease (SCD), reported by Shenoy et al, is an important step in extending curative therapy to more children with severe disease.1
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free
